All Articles by Author:


Delineating the Role of Osteoprotegerin as a Marker of Breast Cancer Risk among Women with a BRCA1 Mutation

[Hereditary Cancer in Clinical Practice] Scientists provide a review of the emerging preclinical and epidemiologic evidence implicating the dysregulation of progesterone-mediated receptor activator of nuclear factor κB signaling in the pathogenesis of BRCA1-associated breast cancer.

LncRNA PCAT1 Activates SOX2 and Suppresses Radioimmune Responses via Regulating cGAS/STING Signaling in Non-Small Cell Lung Cancer

[Clinical and Translational Medicine] Investigators explored the impacts of prostate cancer-associated ncRNA transcripts 1 (PCAT1) on tumorigenesis and radioimmune responses and the underlying molecular mechanisms in NSCLC.

Progenitor Potential of Lung Epithelial Organoid Cells in a Transplantation Model

[Cell Reports] The authors transplanted organoid cells derived from alveolar type II cells enriched by SCA1-negative status or multipotent SCA1-positive progenitor cells into injured mouse lungs.

Caspase-9b Drives Cellular Transformation, Lung Inflammation, and Lung Tumorigenesis

[Molecular Cancer Research] A transgenic mouse model expressing human Caspase-9b in the lung pneumocytes developed inflammatory lung lesions, which correlated with enhanced activation of the NF-κB pathway and increased influx of immunosuppressive MDSCs in contrast to wild-type mice.

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-small Cell Lung Cancer

[Clinical Cancer Research] A retrospective database query identified patients with KRAS-mutant NSCLC to understand their propensity to develop brain metastases.

Cancer Stem-Like Cells Evade CD8+CD103+ Tumor-Resident Memory T (TRM) Lymphocytes by Initiating an Epithelial-to-Mesenchymal Transition Program in a Human Lung Tumor Mode

[Journal For Immunotherapy of Cancer] Researchers supported the rational design of immunotherapeutic strategies targeting cancer stem cells to optimize their responsiveness to local CD8+CD103+ TRM cells for more efficient anticancer treatments.


Truqap Plus Faslodex Approved in the EU for Patients with Advanced ER-Positive Breast Cancer

[AstraZeneca] AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with ER-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.

Breast Cancer Exploits Neural Signaling Pathways for Bone-to-Meninges Metastasis

[Science] Scientists applied a combination of intravital and ex vivo three-dimensional confocal microscopy, micro–computed tomography, and histologic analyses to mouse models of bone-metastatic breast cancer and leptomeninges (LM) metastasis,. They demonstrated that breast cancer cells could traffic to the LM from the bone marrow through abluminal emissary vein migration.

RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis

[Cancer Research] Investigators employed a CRISPR/Cas9 screening strategy that revealed RUVBL1 and RUVBL2 as putative targets. Loss of RUVBL1/2 preferentially impaired the growth of YTHDF1-high colorectal cancer (CRC) cells, patient-derived primary CRC organoids, and subcutaneous xenografts.